<DOC>
	<DOCNO>NCT00991029</DOCNO>
	<brief_summary>A transient ischemic attack ( TIA ) transient episode neurological dysfunction cause focal brain , spinal cord , retinal ischemia , without acute infarction . An ischemic stroke cerebral infarction . In POINT , eligibility limit brain TIAs minor ischemic stroke ( NIH Stroke Scale [ NIHSS ] score less equal 3 ) . TIAs common [ 25 ] , often harbinger disable stroke . Approximately 250,000-350,000 TIAs diagnose year US . Given median survival 8 year [ 32 ] , approximately 2.4 million TIA survivor . In national survey , one fifteen 65 year old report history TIA [ 33 ] , equivalent prevalence 2.3 million old Americans . Based prevalence undiagnosed transient neurological event , true incidence TIA may twice high rate diagnosis [ 33 ] . Based review National Inpatient Sample 1997-2003 , average 200,000 hospital admission TIA year , annual charge climb quickly period $ 2.6 billion 2003 . Composite endpoint new ischemic vascular event : ischemic stroke , myocardial infarction ischemic vascular death 90 day .</brief_summary>
	<brief_title>Platelet-Oriented Inhibition New TIA Minor Ischemic Stroke ( POINT ) Trial</brief_title>
	<detailed_description>Platelet-Oriented Inhibition New TIA minor ischemic stroke ( POINT ) Trial , prospective , randomize , double-blind , multicenter trial primary null hypothesis , patient TIA minor ischemic stroke treat aspirin 50-325 mg/day , difference event-free survival 90 day treat clopidogrel ( 600 mg load dose 75 mg/day ) compare placebo subject randomize within 12 hour time last known free new ischemic symptom . Its primary objective determine whether clopidogrel 75 mg/day mouth load dose 600 mg clopidogrel effective preventing major ischemic vascular event ( ischemic stroke , myocardial infarction , ischemic vascular death ) 90 day initiate within 12 hour TIA minor ischemic stroke onset patient receive aspirin 50-325 mg/day ( dose 150-200 mg daily 5 day follow 75-100 mg daily strongly recommend ) . Patients 18 year age high-risk TIA ( define ABCD2 score great equal 4 ) minor ischemic stroke ( NIHSS le equal 3 ) treat within 12 hour time last known free new ischemic symptom enrol . Subjects randomize 1:1 ( clopidogrel : placebo ) , control clinical center . A study participant 's eligibility determine site personnel prior access Randomization Module WebDCUâ„¢ , web-enabled clinical trial management system develop NETT Statistics Data Management Center ( SDMC ) Medical University South Carolina ( MUSC ) .Qualified users access Randomization Interface complete protocol-specific eligibility checklist . If Randomization Interface find patient eligible base information provide , randomization number confirmatory e-mail generate . Each subject follow 90 day randomization ; trial complete 7 year . A total 5,840 patient recruit . Recruitment occur 90 month , goal rate 0.40 subjects/site/month US site , goal rate 0.47 subjects/site/month OUS site . Current participate site find : http : //www.pointtrial.org/node/18 .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Neurological deficit ( base history exam ) attribute focal brain ischemia EITHER : High risk TIA : Complete resolution deficit time randomization AND ABCD2 score ( great equal ) 4 OR Minor ischemic stroke : residual deficit NIHSS ( less equal ) 3 time randomization Ability randomize within 12 hour time last known free new ischemic symptom . Head CT MRI ruling hemorrhage pathology , vascular malformation , tumor , abscess , could explain symptom contraindicate therapy . Ability tolerate aspirin 50325 mg/day . Exclusion Criteria Age &lt; 18 year TIA symptom limit isolated numbness , isolate visual change , isolate dizziness/vertigo . In judgment treat physician , candidate thrombolysis , endarterectomy endovascular intervention , unless subject decline endarterectomy endovascular intervention time evaluation eligibility . Receipt intravenous intraarterial thrombolysis within 1 week prior index event . Gastrointestinal bleed major surgery within 3 month prior index event . History nontraumatic intracranial hemorrhage . Clear indication anticoagulation ( e.g. , warfarin , heparin ) anticipate study period ( atrial fibrillation , mechanical heart valve , deep venous thrombosis , pulmonary embolism , antiphospholipid antibody syndrome , hypercoagulable state ) . Qualifying ischemic event induce angiography surgery . Severe noncardiovascular comorbidity life expectancy &lt; 3 month . Contraindication clopidogrel aspirin . Known allergy Severe renal ( serum creatinine &gt; 2 mg/dL 176.8umol/L ) hepatic insufficiency ( prior concurrent diagnosis , International Normalized Ratio ( INR ) &gt; 1.5 resultant complication , variceal bleeding , encephalopathy , icterus ) Hemostatic disorder systemic bleed past 3 month Current thrombocytopenia ( platelet count &lt; 100 x10^9/l ) neutropenia ( &lt; 1 x10^9/l ) History druginduced hematologic hepatic abnormality Anticipated requirement longterm ( &gt; 7 day ) nonstudy antiplatelet drug ( eg , dipyridamole , clopidogrel , ticlopidine ) , Nonsteroidal Antiinflammatory Drugs ( NSAIDs ) affect platelet function ( prior vascular stent arthritis ) . Inability swallow medication . At risk pregnancy : premenopausal post menopausal woman within 12 month last menses without negative pregnancy test commit adequate birth control ( e.g. , oral contraceptive , two method barrier birth control , abstinence ) . Unavailability followup . Signed date informed consent obtain patient . Other neurological condition would complicate assessment outcome followup . Ongoing treatment another study investigational therapy may potentially interact study drug , treatment study within last 7 day . Previously enrol POINT study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Transient Ischemic Attack</keyword>
	<keyword>TIA</keyword>
	<keyword>minor stroke</keyword>
</DOC>